Trouble reading this e-mail? View it in your browser.

EFPIA
Newsletter
1 October 2015
Header
Header image
News

News

EFPIA, Siffa and Latvian Government Meet to Forge Stability Pact and Boost Patient Access to Medicines
25 September 2015

On 25 September 2015, senior representatives of the pharmaceutical industry, including Richard Bergström, Director General of EFPIA, Imants Sinka and Dita-Erna Sile, respectively Chairman of [...] Read more

News

EFPIA Launches Robust Principles to Secure a Competitive European Off-Patent Biologic Medicines Market
30 September 2015

Comprehensive EFPIA principles launched 30th September 2015, are designed to create and secure a sustainable and competitive off-patent biologic medicines market that balances efficient patient [...] Read more

News

Global Pharmaceutical Associations Welcome MEDICRIME Convention, Landmark Tool to Curb Global Medicines Counterfeiting
01 October 2015

  The global innovative and generic/biosimilar pharmaceutical industries welcome the entry into force of the Medicrime Convention and encourage countries worldwide to sign and ratify it. The [...] Read more

From our blog

From our blog

Ventures and vultures
29 September 2015 by Richard Bergström

The last year has exposed two species in the biopharma world: those that want to advance science and make money through providing new medicines to patients. The other type, typified by companies like Valeant and Turing, simply wants to buy existing medicines, jack up the prices, and retire to the Bahamas.

Read more

From our blog

Second take-off
29 September 2015 by Richard Bergström

I never got to fly Concorde, the world’s first (and so far only) supersonic commercial airplane. One colleague, having experienced the flight, described how, after half an hour in the air, there is a “second take-off” accelerating from 1000 km/h to supersonic speed. I think biopharmaceutical research is about to experience a second take-off.

Read more

From our blog

Data protection regulation – harmonise or compromise? (Guest blog)
30 September 2015 by Nick Meade, Director of Policy at Genetic Alliance UK

The way we use data has changed enormously since the last EU-wide legislation on data protection was passed twenty years ago. We now have more data about ourselves in the cloud than would have fitted on our home computers in 1995. Data use and data volume has changed in the worlds of healthcare and biomedical research just as much as it has changed in our personal lives. The genomic revolution is well underway, and the data from each and every human genome sequenced will not fit on the computer I sit at today. We have ‘big data’ too, which has just as much potential to revolutionise our knowledge about our own health.

Read more

From our blog

EFPIA’s Principles Offer a Non-Discriminatory Solution to Enable Competition for Off-Patent Biologic Medicines
30 September 2015 by Douglas Gregory, Chair of EFPIA Biologics LoE WG

Competition from biosimilar medicines provides a major opportunity for cost savings throughout Europe by making a significant contribution to the sustainability of National Healthcare Systems (NHSs) whilst improving patient access to innovative medicines in both the short and long term.

Read more

From our blog

Rapidly advancing pharmaceutical science and innovation presents new challenges
29 September 2015 by Richard Bergström

Last year I wrote a blog called “From me-too to too-much”, underlining that the pipeline of new medicines is better than ever. The results of EFPIA members rapidly advancing science and innovation are coming to fruition with recent approvals of cures for hepatitis C, game-changing cancer medicines, and medicines that reduce mortality due to heart failure or high cholesterol. 

Read more

From our blog

Reflections on disclosure at ECC2015
30 September 2015 by Andrew Powrie-Smith

As we pack up the stand after four fascinating days at the European Cancer Congress 2015, I have a little time to reflect on some of the conversations we have had on industry’s move to disclose publicly payments to health professionals.

Read more

Events calendar

Events Calendar

EFPIA Health Collaboration Summit 28-29 October 2015
From 28/10/2015 to 29/10/2015 (Brussels)

The event will bring together senior figures from patient organisations, healthcare systems and industry to discuss outcomes driven, sustainable healthcare in Europe and the role of transparency in developing effective working relationships, capacity building and governance.

In order to share best practice on multi-stakeholder collaborations that benefit patients and healthcare systems, EFPIA and the Patient Think Tank are establishing the Health Collaboration Award.

The Award is open to multi-stakeholder collaborative projects on local, national and EU level that benefit patients. Entrants must include patient organisations and industry partners.

 

 

 

 

 

Please note that the event is full and registration is now closed. Please note that submissions for the Awards closed on 5 October. 

For more information, click here or contact zsofia.bakonyi@efpia.eu.

Read more

Events Calendar

Emerging Medicinal Products – from laboratory to patient use
On 14/12/2015 (De Vere Centre, 1 Westferry Circus, Canary Wharf, London)

The fourth annual regulatory policy summit has been organised by EBE and the European Medicines Agency (EMA).

 

 

 

Read more

Events Calendar

Better Science, Better Health: New Healthcare Models
From 27/10/2015 to 28/10/2015 (Washington DC)

There are currently multiple global initiatives investigating ways to improve and accelerate the way we bring much-needed new medicines to patients. How do we collaborate internationally to create better patient outcomes in the emerging world of precision medicine?

Read more

Events Calendar

Implement, Integrate & Optimise Your Sustainable Serialisation Strategy
From 02/11/2015 to 04/11/2015 (Geneva)

Join the Pharma Serialisation & Traceability 2015 Summit in Geneva! With 22+ presentations from big pharma, CMOs, generics and SMEs, and with the chance to meet directly with regulatory bodies and associations, this event simply cannot be missed.

Read more

Documents

From our blog

EFPIA Policy Principles for Off-patent Biologic Medicines in Europe
30 September 2015 (Position Papers)

Read more

From our blog

EFPIA policy principles framework for off-patent biologic medicines in Europe
30 September 2015 (Presentations)

Read more

What we are reading

What we are reading

Securing health in Europe: balancing priorities, sharing responsibilities
30 September 2015 (WHO)

Read more

About EFPIA updates
Unsubscribe to be removed from this mailing list | Update your subscription

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 34 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
Leopold Plaza Building
Rue du Trône 108
B-1050 Brussels (Belgium)
Tel: +32 (0)2 626 25 55
E-mail: communications@efpia.eu
Follow EFPIA
Twitter LinkedIn Youtube Google + Pinterest E-mail